camrelizumab
Showing 26 - 50 of 388
Gestational Trophoblastic Neoplasia Trial in Beijing (Camrelizumab plus apatinib CohortA, Camrelizumab plus apatinib Cohort B)
Recruiting
- Gestational Trophoblastic Neoplasia
- Camrelizumab plus apatinib CohortA
- Camrelizumab plus apatinib Cohort B
-
Beijing, ChinaPeking Union Medical College Hospital
Jul 7, 2022
Squamous Cell Carcinoma of Head and Neck Trial in Shanghai (Camrelizumab+cetuximab+chemo)
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
-
Shanghai, ChinaFudan University
Jan 4, 2023
Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)
Enrolling by invitation
- Germline BRCA-mutated HER2-negative Breast Cancer
-
Beijing, Beijing, ChinaBreast Cancer, Peking University People's Hospital
Nov 14, 2022
Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)
Recruiting
- Colon Cancer
- Neoadjuvant Therapy
- Camrelizumab , apatinib and chemotherapy
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Jan 27, 2023
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2),Immunotherapy
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Dec 6, 2022
Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)
Not yet recruiting
- Second Line Treatment of Gastric Cancer
- Camrelizumab
- +2 more
- (no location specified)
Dec 20, 2022
Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
- (no location specified)
Aug 17, 2023
Multicenter, Prospective, Real World Study of Camrelizumab in
Not yet recruiting
- NSCLC
- Camrelizumab
- (no location specified)
Sep 19, 2022
Endometrial Cancer Trial (Anlotinib + Camrelizumab)
Not yet recruiting
- Endometrial Cancer
- Anlotinib + Camrelizumab
- (no location specified)
Sep 26, 2022
Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)
Not yet recruiting
- Melanoma
- +6 more
- Camrelizumab
- (no location specified)
Aug 21, 2022
Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Camrelizumab
- +4 more
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital
Nov 6, 2022
Hepatocellular Carcinoma Trial in Nanjing (Camrelizumab, TACE, Apatinib)
Recruiting
- Hepatocellular Carcinoma
- Camrelizumab
- +2 more
-
Nanjing, Jiangsu, ChinaZhongda Hospital
Sep 8, 2022
Hepatocellular Carcinoma Trial (TACE+Camrelizumab+Apatinib mesylate, TACE)
Recruiting
- Hepatocellular Carcinoma
- TACE+Camrelizumab+Apatinib mesylate
- TACE
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Oct 17, 2022
Adrenocortical Carcinoma Trial (Camrelizumab)
Recruiting
- Adrenocortical Carcinoma
- Camrelizumab
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Dec 16, 2022
Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer Trial in Tianjin (fluzoparib+chidamide, fluzoparib+camrelizumab)
Recruiting
- Advanced HER2 Negative Breast Carcinoma
- HRD+Breast Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Sep 27, 2022
Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)
Active, not recruiting
- Non-squamous Non-small-cell Lung Cancer
- Brain Metastases
- Camrelizumab
- +2 more
-
Guangzhou, Guangzhou, ChinaLi-Kun Chen
Nov 13, 2022
Pancreas Cancer Trial (surufatinib + camrelizumab + nab-paclitaxel + S-1, nab-paclitaxel + gemcitabine)
Recruiting
- Pancreatic Cancer
- +3 more
- surufatinib + camrelizumab + nab-paclitaxel + S-1
- nab-paclitaxel + gemcitabine
-
Beijing, ChinaChinese PLA General Hospital
Sep 26, 2022
Triple-Negative Breast Cancer Trial in Shanghai (Camrelizumab plus Famitinib with/without nab-Palitaxel)
Not yet recruiting
- Triple-Negative Breast Cancer
- Camrelizumab plus Famitinib with/without nab-Palitaxel
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jan 2, 2023
Stomach Tumors, Digestive System Tumors, Tumors Trial in Fuzhou (Camrelizumab, SOX, Surgery)
Active, not recruiting
- Stomach Neoplasms
- +5 more
- Camrelizumab
- +2 more
-
Fuzhou, Fujian, ChinaThe Second Affiliated Hospital of Fujian Medical University
Nov 1, 2022
Oral Squamous Cell Carcinoma Trial in Shanghai (Camrelizumab Plus Docetaxel and Cisplatin)
Recruiting
- Oral Squamous Cell Carcinoma
- Camrelizumab Plus Docetaxel and Cisplatin
-
Shanghai, Shanghai, ChinaShanghai Ninth People's Hospital affiliated to Shanghai Jiao Ton
Nov 9, 2022
Hepatocellular Carcinoma Trial (Hepatectomy Combined With Camrelizumab and Apatinib)
Recruiting
- Hepatocellular Carcinoma
- Hepatectomy Combined With Camrelizumab and Apatinib
-
Nanning, ChinaGuangxi Medical University Cancer Hospital
Sep 4, 2022
Gastric Cancer Trial in Shanghai (camrelizumab+chemo, Chemotherapy)
Recruiting
- Gastric Cancer
-
Shanghai, Shanghai, ChinaRuijin Hospital
Aug 9, 2022
Advanced Solid Tumor Trial (Linperlisib Tablet)
Not yet recruiting
- Advanced Solid Tumor
- Linperlisib Tablet
- (no location specified)
Jun 20, 2022
Solid Tumor Trial in Henan (Camrelizumab combined with apatinib mesylate)
Recruiting
- Solid Tumor
- Camrelizumab combined with apatinib mesylate
-
Henan, ChinaHenan Tumor Hospital
May 15, 2022
Esophageal Carcinoma Trial in Tianjin (camrelizumab)
Recruiting
- Esophageal Carcinoma
- camrelizumab
-
Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Jul 25, 2022